Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 17.500 NA in 2016. This records an increase from the previous number of 17.200 NA for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 17.500 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 21.600 NA in 2000 and a record low of 17.200 NA in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

The country with the highest projected number of diabetics in 2045 is China, with some projected 174 million people between the ages of 20 and 79 suffering from diabetes. It is forecast that the number of adults with the condition in Pakistan will exceed that of the United States by 2045.

Number of diabetics worldwide

Diabetes is a condition that causes the pancreas to stop (or severely reduce) the production of insulin, a hormone needed to regulate blood sugar levels. Many people worldwide live with diabetes: in 2021, a total of about 537 million people had diabetes. This number is projected to reach an estimated 783 million by the year 2045.

Global diabetes costs

In 2021, 966 billion U.S. dollars were spent on diabetes-related healthcare treatment worldwide. Of 2021’s global total, almost 380 billion U.S. dollars were spent in the United States alone. Global healthcare expenditures for diabetes are expected to increase by 84 billion U.S. dollars by 2045.

Market Overview:

United States digital diabetes management market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.2 Billion by 2032, exhibiting a growth rate (CAGR) of 18.64% during 2024-2032. The rising emphasis on continuous patient engagement, along with the growing popularity of personalized healthcare, is primarily driving the market growth.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2032
Historical Years	2018-2023
Market Size in 2023	US$ 3.3 Billion
Market Forecast in 2032	US$ 15.2 Billion
Market Growth Rate (2024-2032)	18.64%

Digital diabetes management involves employing technology and digital solutions to support individuals in overseeing and regulating their diabetes condition. These digital tools and applications encompass diverse features that assist in monitoring blood glucose levels, ensuring medication adherence, tracking physical activity, and managing dietary intake. Through the utilization of smartphones, wearable devices, and cloud-based platforms, digital diabetes management enables the real-time collection and analysis of data, promoting enhanced self-management and patient engagement. A notable advantage of this approach is its capacity to deliver personalized insights and practical recommendations based on the gathered data. This empowers individuals to make well-informed decisions regarding their lifestyle and treatment choices. Moreover, healthcare providers gain access to a comprehensive overview of the patient's health, facilitating remote monitoring and timely interventions as needed. Additionally, these technologies play a pivotal role in improving patient outcomes by sustaining continuous engagement and motivation through interactive features and educational resources. They also streamline communication between patients and healthcare professionals, ultimately enhancing the overall quality of patient care.

United States Digital Diabetes Management Market Trends:

The United States digital diabetes management market is witnessing a surge in growth, driven by key drivers and emerging trends that underscore the transformative impact of technology on diabetes care. Technological advancements stand out as a primary driver, with the integration of smartphones, wearable devices, and cloud-based platforms enhancing the accessibility and effectiveness of digital diabetes management solutions. Moreover, as the number of individuals diagnosed with diabetes continues to grow, there is an increasing demand for innovative solutions that facilitate personalized and efficient self-management. Besides this, interconnectivity and data-sharing capabilities are shaping the market, enabling seamless communication between patients and healthcare providers. Additionally, remote monitoring and timely interventions are becoming standard practices, enhancing patient care and facilitating more proactive healthcare approaches. Apart from this, interactive features and educational resources embedded in these technologies play a crucial role in sustaining patient motivation and promoting long-term adherence to diabetes management plans. Furthermore, technological advancements, the increasing diabetes prevalence, and personalized healthcare approaches are expected to fuel the market growth across the country over the forecasted period.

United States Digital Diabetes Management Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on product type and device type.

Product Type Insights:

https://www.imarcgroup.com/CKEditor/7b549f7f-f20e-4e5b-94d9-5e4962272768other-regions1.webp" style="height:450px; width:800px" />

• Smart Glucose Meter
• Smart Insulin Pumps
• Smart Insulin Pens
• Apps
  

The report has provided a detailed breakup and analysis of the market based on the product type. This includes smart glucose meter, smart insulin pumps, smart insulin pens, and apps.

Device Type Insights:

• Handheld Devices
• Wearable Devices
  

A detailed breakup and analysis of the market based on the device type have also been provided in the report. This includes handheld devices and wearable devices.

Regional Insights:

https://www.imarcgroup.com/CKEditor/4b465987-57d3-4cd0-8106-e8e0bddefdd8other-regions8.webp" style="height:450px; width:800px" />

• Northeast
• Midwest
• South
• West
  

The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

United States Digital Diabetes Management Market Report Coverage:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Scope of the Report	Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Product Type Device Type Region
Product Types Covered	Smart Glucose Meter, Smart Insulin Pumps, Smart Insulin Pens, Apps
Device Types Covered	Handheld Devices, Wearable Devices
Regions Covered	Northeast, Midwest, South, West
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

• How has the United States digital diabetes management market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the United States digital diabetes management market?
• What is the breakup of the United States digital diabetes management market on the basis of product

www.insight.hdrhub.org/about-us

Background: Diabetes mellitus affects over 3.9 million people in the United Kingdom (UK), with over 2.6 million people in England alone. More than 1 million people living with diabetes are acutely admitted to hospital due to complications of their illness every year. Cardiovascuar disease is the most prevalent cause of morbidity and mortality in people with diabetes. Diabetic retinopathy (DR) is a common microvascular complication of type 1 and type 2 diabetes and remains a major cause of vision loss and blindness in those of working age. This dataset includes the national screening diabetic grade category (seven categories from R0M0 to R3M1) from the Birmingham, Solihull and Black Country DR screening program (a member of the National Health Service (NHS) Diabetic Eye Screening Programme) and the University Hospitals Birmingham NHS Trust cardiac outcome data.

Geography: The West Midlands has a population of 5.9 million. The region includes a diverse ethnic, and socio-economic mix, with a higher than UK average of minority ethnic groups. It has a large number of elderly residents but is the youngest population in the UK. There are particularly high rates of diabetes, physical inactivity, obesity, and smoking.

Data sources:
1. The Birmingham, Solihull and Black Country Data Set, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. They manage over 200,000 diabetic patients, with longitudinal follow-up up to 15 years, making this the largest urban diabetic eye screening scheme in Europe. 2. The Electronic Health Records held at University Hospitals Birmingham NHS Foundation Trust is one of the largest NHS Trusts in England, providing direct acute services and specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds and 100 ITU beds. UHB runs a fully electronic healthcare record for systemic disease.

Scope: All Birmingham, Solihull and Black Country diabetic eye screened participants who have been admitted to UHB with a cardiac related health concern from 2006 onwards. Longitudinal and individually linked with their diabetic eye care from primary screening data and secondary care hospital cardiac outcome data including • Demographic information (including age, sex and ethnicity) • Diabetes status • Diabetes type • Length of time since diagnosis of diabetes • Visual acuity • The national screening diabetic screening grade category (seven categories from R0M0 to R3M1) • Diabetic eye clinical features • Reason for sight and severe sight impairment • ICD-10 and SNOMED-CT codes pertaining to cardiac disease • Outcome

Website: https://www.retinalscreening.co.uk/

According to Cognitive Market Research, the global Diabetic Tests market size is USD XX million in 2023 and will expand at a compound annual growth rate (CAGR) of 9.80% from 2023 to 2030.

North America held the major market of more than 40% of the global revenue and will grow at a compound annual growth rate (CAGR) of 8.0% from 2023 to 2030.
Europe market of more than 30% of the global revenue and will grow at a compound annual growth rate (CAGR) of 8.3% from 2023 to 2030.
Asia Pacific held the fastest growing market of more than 23% of the global revenue and will grow at a compound annual growth rate (CAGR) of 11.8% from 2023 to 2030
Latin America market of more than 5% of the global revenue and will grow at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2030.
Middle East and Africa market of more than 2.00% of the global revenue and will grow at a compound annual growth rate (CAGR) of 9.5% from 2023 to 2030
The demand for Diabetic Tests is rising due to the technology advancements in diabetes diagnostics and increasing obesity levels.
Demand for blood glucose monitors remains higher in the Diabetic Tests market.
The home care category held the highest Diabetic Tests market revenue share in 2023.

Technological Advancements in Glucose Monitoring to Provide Viable Market Output

Technological innovations in diabetic testing have been a key driver in the Diabetic Tests market. Continuous advancements in glucose monitoring devices, such as continuous glucose monitors (CGMs) and minimally invasive sensors, have enhanced the accuracy, convenience, and efficiency of glucose level monitoring. These technologies empower individuals with diabetes to manage their condition more effectively by providing real-time data, reducing the need for frequent blood draws.

March 2022: Ministry of Health Canada released Health Network System (HNS) changes to reimbursement of blood glucose test strips under the Ontario Drug Benefit (ODB) Program.

(Source:files.ontario.ca/moh-executive-officer-notice-en-2022-03-07.pdf)

E-Commerce and Online Retail Stores to Propel Market Growth

The growth of e-commerce and online retail has significantly impacted the Diabetic Tests market. Consumers now have easy access to a wide range of Diabetic Tests from the comfort of their homes. Online platforms offer convenience, product variety, and reviews, allowing shoppers to make informed choices. This shift in shopping behavior has fueled market expansion, making Diabetic Tests more accessible to a global audience, thereby contributing to increased sales and brand awareness within this niche market.

In February 2020, Abbott (US) received US FDA approval for the use of FreeStyle Libre 14-day Flash glucose monitoring systems in hospitals.

(Source:www.abbott.com/corpnewsroom/products-and-innovation/freestyle-libre-14-day.html)

Market Restraints of the Diabetic Tests

Challenges in Affordability and Accessibility to Restrict Market Growth

The Diabetic Tests market faces a key restraint associated with issues of affordability and accessibility. While advanced technologies have improved the accuracy and efficiency of diabetic tests, their widespread adoption can be hindered by economic disparities and uneven healthcare infrastructure. Affordability remains a concern for individuals in lower-income brackets, limiting their access to essential testing tools. Additionally, the availability of these tests may be inconsistent, particularly in regions with inadequate healthcare resources. Overcoming these challenges requires collaborative efforts from healthcare providers, policymakers, and industry stakeholders to ensure that innovative diabetic tests are both economically viable and accessible to a broad spectrum of the population.

Impact of COVID–19 on the Diabetic Tests Market

The COVID-19 pandemic significantly impacted the Diabetic Tests market as it brought about disruptions in healthcare systems, altered patient behavior, and influenced market dynamics. The initial phases of the pandemic witnessed disruptions in routine medical care, including diagnostic testing, due to lockdowns, overwhelmed healthcare facilities, and patients' hesitancy to visit healthcare settings. This led to delays in routine diabetic tests and screenings, affecting disease management and early detection. However, as the healthcare sector adapted to the challenges, there was an increased ...

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

The Health Survey for England series was designed to monitor trends in the nation's health; estimating the proportion of people in England who have specified health conditions, and the prevalence of risk factors and behaviours associated with these conditions. The surveys provide regular information that cannot be obtained from other sources. The surveys have been carried out since 1994 by the Joint Health Surveys Unit of NatCen Social Research and the Research Department of Epidemiology and Public Health at UCL. Each survey in the series includes core questions, e.g. about alcohol and smoking, and measurements (such as blood pressure, height and weight, and analysis of blood and saliva samples), and modules of questions on topics that vary from year to year. The trend tables show data for available years between 1993 and 2016 for adults (defined as age 16 and over) and for children. The survey samples cover the population living in private households in England. In 2016 the sample contained 8,011 adults and 2,056 children and 5,049 adults and 1,117 children had a nurse visit. We would very much like your feedback about whether some proposed changes to the publications would be helpful and if the publications meet your needs. This will help us shape the design of future publications to ensure they remain informative and useful. Please answer our reader feedback survey on Citizen Space which is open until 18 June 2018.

Multinomial regression model was applied to analyze risk factors of prediabetes and diabetes. Odds ratio (OR) (95% confidence interval) for assessment of associations of risk factors with outcome of prediabetes and diabetes in 3173 study subjects were presented.Multivariate logistic regression analysis of risk factors of diabetes.

2013 Medicaid figures for southeast Michigan counties of Wayne, Oakland, and Macomb at the ZCTA level. This data represent number of visits, they are not counts of different individuals, only of visits. One person could have had multiple visits and each visit would be counted. Blank cells indicate no visits. Whether a visit is coded as a hospital or ER visit depends on the DRG, Diagnosis-Related Group; that is, the diagnosis.

This multi-scale map shows life expectancy - a widely-used measure of health and mortality. From the 2020 County Health Rankings page about Life Expectancy:"Life Expectancy is an AverageLife Expectancy measures the average number of years from birth a person can expect to live, according to the current mortality experience (age-specific death rates) of the population. Life Expectancy takes into account the number of deaths in a given time period and the average number of people at risk of dying during that period, allowing us to compare data across counties with different population sizes.Life Expectancy is Age-AdjustedAge is a non-modifiable risk factor, and as age increases, poor health outcomes are more likely. Life Expectancy is age-adjusted in order to fairly compare counties with differing age structures.What Deaths Count Toward Life Expectancy?Deaths are counted in the county where the individual lived. So, even if an individual dies in a car crash on the other side of the state, that death is attributed to his/her home county.Some Data are SuppressedA missing value is reported for counties with fewer than 5,000 population-years-at-risk in the time frame.Measure LimitationsLife Expectancy includes mortality of all age groups in a population instead of focusing just on premature deaths and thus can be dominated by deaths of the elderly.[1] This could draw attention to areas with higher mortality rates among the oldest segment of the population, where there may be little that can be done to change chronic health problems that have developed over many years. However, this captures the burden of chronic disease in a population better than premature death measures.[2]Furthermore, the calculation of life expectancy is complex and not easy to communicate. Methodologically, it can produce misleading results caused by hidden differences in age structure, is sensitive to infant and child mortality, and tends to be overestimated in small populations."Click on the map to see a breakdown by race/ethnicity in the pop-up: Full details about this measureThere are many factors that play into life expectancy: rates of noncommunicable diseases such as cancer, diabetes, and obesity, prevalence of tobacco use, prevalence of domestic violence, and many more.Data from County Health Rankings 2020 (in this layer and referenced below), available for nation, state, and county, and available in ArcGIS Living Atlas of the World

Snapshot img

Continuous Glucose Monitoring (CGM) Market Size 2024-2028

The continuous glucose monitoring (cgm) market size is forecast to increase by USD 2.94 billion at a CAGR of 6.78% between 2023 and 2028.

The market is experiencing significant growth, driven primarily by the rising number of diabetic patients worldwide. According to the International Diabetes Foundation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. This increasing diabetic population necessitates the need for advanced glucose monitoring solutions, leading to a in demand for CGMs. Another key trend fueling market growth is the increasing adoption of home healthcare devices. CGMs enable patients to monitor their glucose levels continuously, providing real-time data that can help them manage their diabetes more effectively. This is particularly beneficial for those with diabetes who require frequent monitoring, such as those with type 1 diabetes or those with complications. Additionally, the convenience and flexibility offered by CGMs are driving their adoption, as patients no longer need to visit healthcare facilities regularly for glucose tests. However, the market also faces challenges, including the high cost of CGMs and the lack of awareness and education about the benefits of continuous glucose monitoring. Despite these challenges, there are opportunities for companies to capitalize on the growing demand for CGMs. Investing in research and development to create more affordable and user-friendly solutions, as well as increasing awareness and education efforts, can help companies capture market share and meet the needs of the growing diabetic population.

What will be the Size of the Continuous Glucose Monitoring (CGM) Market during the forecast period?

Request Free SampleThe market is experiencing significant growth due to the increasing prevalence of diabetes and the growing demand for advanced diabetes management solutions. CGM systems provide real-time glucose level data, enabling better diabetes control and improved diabetes care. These systems offer several advantages over traditional blood glucose monitoring methods, including longer sensor wear time, increased accuracy, and the ability to monitor glucose levels during exercise, sleep, and various lifestyle activities. The integration of CGM with diabetes medication management, diabetes education, and diabetes research is further driving market expansion. The diabetes community continues to advocate for the use of CGM technology as an essential tool for managing diabetes complications, improving diabetes and healthcare outcomes, and enhancing overall diabetes lifestyle. Sensor innovation and comfort, as well as the development of diabetes management apps and solutions, are also contributing to the market's growth. The continuous advancement of sensor technology and the increasing focus on diabetes prevention and genomics are expected to further fuel market expansion.

How is this Continuous Glucose Monitoring (CGM) Industry segmented?

The continuous glucose monitoring (cgm) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ComponentSensorsTransmittersReceiversEnd-userHome careHospitalsOthersGeographyNorth AmericaUSCanadaEuropeGermanyUKAsiaRest of World (ROW)

By Component Insights

The sensors segment is estimated to witness significant growth during the forecast period.Continuous Glucose Monitoring (CGM) involves the use of small glucose sensors that are inserted under the skin to measure interstitial fluid glucose levels continuously. Transmitters connected to these sensors send real-time data to receiver displays or digital health platforms for monitoring. CGM devices offer several advantages over traditional self-monitoring blood glucose methods, including improved patient comfort, reduced calibration needs, and hypoglycemia alerts. Regulatory approval for CGM devices has expanded to include type 2 diabetes and gestational diabetes mellitus, as well as pediatric populations. Technological advancements, such as integrated insulin pumps and wireless network connectivity via 4G networks, enable seamless data management and automated insulin delivery. CGM devices are essential diabetes management tools for individuals with chronic conditions, including high blood pressure, heart disease, and high cholesterol, who are at risk for hypoglycemic conditions. Wearable health devices, including CGM devices and mobile apps, facilitate data tracking, alert systems, and user accuracy, enhancing overall patient monitoring and quality of life. CGM sensors have a long sensor life, reducing replacement costs, and are suitable for home healthcare use.

Get a glance at t

Data for cities, communities, and City of Los Angeles Council Districts were generated using a small area estimation method which combined the survey data with population benchmark data (2022 population estimates for Los Angeles County) and neighborhood characteristics data (e.g., U.S. Census Bureau, 2017-2021 American Community Survey 5-Year Estimates). Data for this indicator are based on self-reported height and weight. Body Mass Index (BMI) is calculated by dividing a person’s weight in kilograms by the square of their height in meters. Individuals with a BMI ≥ 30 are considered to have obesity. Note, while BMI can be helpful in screening for individuals with obesity or overweight, it does not measure how much body fat an individual has or provide any diagnostic information about their overall health.Obesity is associated with increased risk for heart disease, diabetes, and cancer. Cities and communities can help curb the current obesity epidemic by adopting policies that support healthy food retail and physical activity and improve access to preventive care services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

Data include individual-level health data, including results from cardiovascular tests and medical history. This is linked to air quality data at participants' residence. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Data may be requested through the Jackson Heart Study. Format: Data include individual-level health data, including results from cardiovascular tests and medical history. This is linked to air quality data at participants' residence. Since these data contain PII, they cannot be released to ScienceHub. This dataset is associated with the following publications: Weaver, A., A. Bidulescu, G. Wellenius, D. Hickson, M. Sims, A. Vaidyanathan, W. Wu, A. Correa, and Y. Wang. Associations between Air Pollution Indicators and Prevalent and Incident Diabetes among African American Participants in the Jackson Heart Study. Environmental Epidemiology. Wolters Kluwer, Alphen aan den Rijn, NETHERLANDS, 5(3): e140, (2021). Weaver, A., Y. Wang, G. Wellenius, A. Bidulescu, M. Sims, A. Vaidyanathan, D. Hickson, D. Shimbo, M. Abdalla, K. Diaz, and S. Seals. Long-Term Air Pollution and Blood Pressure in an African American Cohort: The Jackson Heart Study. American Journal of Preventive Medicine. Elsevier B.V., Amsterdam, NETHERLANDS, 60(3): 397-405, (2021).

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

DESCRIPTION This table contains data on the percent of residents aged 16 years and older mode of transportation to work for ...

SUMMARY This table contains data on the percent of residents aged 16 years and older mode of transportation to work for California, its regions, counties, cities/towns, and census tracts. Data is from the U.S. Census Bureau, Decennial Census and American Community Survey. The table is part of a series of indicators in the Healthy Communities Data and Indicators Project of the Office of Health Equity. Commute trips to work represent 19% of travel miles in the United States. The predominant mode – the automobile - offers extraordinary personal mobility and independence, but it is also associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Automobile commuting has been linked to stress-related health problems. Active modes of transport – bicycling and walking alone and in combination with public transit – offer opportunities for physical activity, which is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Risk of injury and death in collisions are higher in urban areas with more concentrated vehicle and pedestrian activity. Bus and rail passengers have a lower risk of injury in collisions than motorcyclists, pedestrians, and bicyclists. Minority communities bear a disproportionate share of pedestrian-car fatalities; Native American male pedestrians experience four times the death rate Whites or Asian pedestrians, and African-Americans and Latinos experience twice the rate as Whites or Asians. More information about the data table and a data dictionary can be found in the About/Attachments section.

ind_id - Indicator ID ind_definition - Definition of indicator in plain language reportyear - Year that the indicator was reported race_eth_code - numeric code for a race/ethnicity group race_eth_name - Name of race/ethnic group geotype - Type of geographic unit geotypevalue - Value of geographic unit geoname - Name of a geographic unit county_name - Name of county that geotype is in county_fips - FIPS code of the county that geotype is in region_name - MPO-based region name; see MPO_County list tab region_code - MPO-based region code; see MPO_County list tab mode - Mode of transportation short name mode_name - Mode of transportation long name pop_total - denominator pop_mode - numerator percent - Percent of Residents Mode of Transportation to Work,
Population Aged 16 Years and Older LL_95CI_percent - The lower limit of 95% confidence interval UL_95CI_percent - The lower limit of 95% confidence interval percent_se - Standard error of the percent mode of transportation percent_rse - Relative standard error (se/value) expressed as a percent CA_decile - California decile CA_RR - Rate ratio to California rate version - Date/time stamp of a version of data

According to Cognitive Market Research, the global glucose monitoring devices market was valued at USD XX in 2023 and it is expected to grow at a CAGR of XX% from 2024 to 2029.

The global software engineering market will grow significantly by XX% CAGR between 2024 to 2029.
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market.
The report includes an analysis of the regional as well as market trends, key players, application areas, and market growth strategies.
Detailed analysis of Market Drivers, Restraints and Opportunities
North America dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.
The report consists size of the market.

Market Dynamics of Glucose Monitoring Devices

Key Drivers

Improving device synchronized data and accuracy for monitoring the glucose level drives the glucose monitoring device market

One of the most important aspects of the monitoring device is the accuracy with which it measures glucose levels. Accurate glucose monitoring is critical for successful diabetes management because it directly influences treatment decisions and patient outcomes. Several companies have developed advanced versions of conventional blood glucose monitors that are portable and minimally invasive. Many next-generation solutions include connectivity features that allow patients' health data to be captured and shared with medical professionals upon request. Companies are doing continuous innovation on the product for giving exact data to the customers. For Instance, in June 2024 Roche Holding AG receives CE mark for its AI enabled continuous glucose monitoring solution offering critical predictions to people living with 1 and type 2 diabetes n flexible insulin therapy. (source https://www.stocktitan.net/news/RHHBY/roche-receives-ce-mark-for-its-ai-enabled-continuous-glucose-i6j95ac2d9ie.html) Modern devices can now provide reliable and consistent readings, lowering the risk of complications caused by incorrect glucose measurements. Exact readings give patients more control over their blood glucose levels, resulting in fewer episodes of hyperglycemia or hypoglycemia. The development of continuous glucose monitoring (CGM) systems marks a significant technological advancement. Furthermore, accurate glucose monitoring devices are critical for healthcare providers because they allow for precise monitoring and individualized treatment plans. This can lead to more efficient resource utilization and improved patient outcomes, thereby driving market growth. As technology advances, glucose monitoring devices' accuracy is expected to improve even more, solidifying their role in effective diabetes management and expanding their global adoption.

Rising number of diabetes patients will further boost the glucose monitoring devices market

The growing incidence of diabetes among populations in both developed and undeveloped countries is leading to a large patient pool worldwide requiring blood monitoring, leading to an increase in demand for these devices among the patient population. Several factors, including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. For Instance, according to International Diabetes Federation (IDF) in 2021, it was estimated that around 537 million adults had diabetes, and China, India, U.S.A., Brazil and Mexico accounted for an estimated 51.6% of the global diabetes population in 2021. (source https://diabetesatlas.org/#:~:text=Diabetes%20around%20the%20world%20in%202021%3A,%2D%20and%20middle%2Dincome%20countries) A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of glucose monitoring systems globally. Thus, the presence of a large diabetic population with insulin-dependent diabetes, new product introductions by market players, and favorable reimbursement are driving demand and adoption of glucose monitoring devices

Restraints

The high cost of devices hinders the market growth

The glucose monitoring device is expensive and can be painful. Diabetes care devices do not always produce accurate results. Many hospitals and health...